We are live on
!
Find out more
SCM
Soleus Capital Management Portfolio holdings
AUM
$2.47B
1-Year Est. Return
115.63%
This Fund
S&P 500
This Quarter
Est. Return
+11.18%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$900M
AUM Growth
-$66.1M
(-6.9%)
Cap. Flow
-$123M
Cap. Flow
% of AUM
-13.72%
Top 10 Holdings %
Top 10 Hldgs %
42.92%
Holding
115
New
38
Increased
27
Reduced
28
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$34.5M |
| 2 |
United Therapeutics
UTHR
|
+$23.6M |
| 3 |
Humana
HUM
|
+$19.6M |
| 4 |
SkinHealth Systems
SKIN
|
+$14.5M |
| 5 |
Seres Therapeutics
MCRB
|
+$11.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$51.8M |
| 2 |
EXAS
Exact Sciences
EXAS
|
+$30.2M |
| 3 |
Smith & Nephew
SNN
|
+$14.9M |
| 4 |
SI-BONE Inc
SIBN
|
+$10.6M |
| 5 |
ACLX
Arcellx
ACLX
|
+$9.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.82% |
| 2 | Consumer Staples | 2.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCYC
26
Bicycle Therapeutics
BCYC
$269M
| $10.5M | 1.17% |
411,800
| – | – |
|
27
NovoCure
NVCR
$1.73B
| $10.2M | 1.13% |
245,100
+115,100
| +89% | +$7.15M |
|
|
RETA
28
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $9.95M | 1.11% |
97,547
-77,045
| -44% | -$7.29M |
|
|
29
Seres Therapeutics
MCRB
$46.8M
| $9.8M | 1.09% |
+102,299
| New | +$11.1M |
|
30
Bausch Health
BHC
$2.58B
| $9.24M | 1.03% |
+1,155,500
| New | +$8.52M |
|
|
NUVL
31
DELISTED
Nuvalent
NUVL
| $8.98M | 1% |
213,000
-23,900
| -10% | -$904K |
|
32
Iovance Biotherapeutics
IOVA
$1.82B
| $8.73M | 0.97% |
1,239,777
-210,000
| -14% | -$1.5M |
|
33
Illumina
ILMN
$31B
| $8.61M | 0.96% |
+47,185
| New | +$9.55M |
|
34
Natera
NTRA
$38.3B
| $8.21M | 0.91% |
168,800
-125,400
| -43% | -$6.4M |
|
35
AngioDynamics
ANGO
$611M
| $8.02M | 0.89% |
768,500
+543,500
| +242% | +$5.23M |
|
|
THER
36
DELISTED
THERATECHNOLOGIES INC COM
THER
| $7.85M | 0.87% |
9,325,511
+235,000
| +3% | +$198K |
|
37
C4 Therapeutics
CCCC
$385M
| $7.4M | 0.82% |
2,692,020
+305,000
| +13% | +$980K |
|
38
Evolus
EOLS
$385M
| $7.39M | 0.82% |
+1,017,000
| New | +$8.77M |
|
39
Kiniksa Pharmaceuticals
KNSA
$5.8B
| $7.32M | 0.81% |
+519,640
| New | +$6.95M |
|
|
EXAS
40
DELISTED
Exact Sciences
EXAS
| $6.53M | 0.73% |
69,500
-387,000
| -85% | -$30.2M |
|
41
BridgeBio Pharma
BBIO
$15.7B
| $6.26M | 0.7% |
364,000
| – | – |
|
42
Transmedics
TMDX
$2.64B
| $6.23M | 0.69% |
74,200
+55,200
| +291% | +$4.23M |
|
43
Alkermes
ALKS
$8.22B
| $6.08M | 0.68% |
194,400
-35,600
| -15% | -$1.08M |
|
44
Pharvaris
PHVS
$2.28B
| $5.93M | 0.66% |
391,900
+55,000
| +16% | +$532K |
|
45
Tango Therapeutics
TNGX
$4.43B
| $5.9M | 0.66% |
+1,776,897
| New | +$6.39M |
|
46
Viking Therapeutics
VKTX
$3.7B
| $5.46M | 0.61% |
336,700
-123,300
| -27% | -$2.58M |
|
47
Xeris Biopharma Holdings
XERS
$1.39B
| $5.38M | 0.6% |
+2,054,105
| New | +$5.23M |
|
|
AVDL
48
DELISTED
Avadel Pharmaceuticals
AVDL
| $5.06M | 0.56% |
+307,000
| New | +$3.99M |
|
49
BioMarin Pharmaceuticals
BMRN
$11.6B
| $5.01M | 0.56% |
+57,800
| New | +$5.44M |
|
50
Mirum Pharmaceuticals
MIRM
$6.46B
| $4.55M | 0.51% |
176,000
-66,000
| -27% | -$1.76M |
|
Similar funds
TW
M
SG
BW
BL
FFA
GWM
Q
Soleus Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Soleus Capital Management held 115 positions worth $900M, down 6.9% from $966M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Soleus Capital Management withdrew a net $123M in Q2 2023, closing 14 positions and reducing 28 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $51.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 81% a quarter earlier, followed by Consumer Staples.
Against the trend, Soleus Capital Management opened a new position in Teva Pharmaceuticals worth $32M.
- Soleus Capital Management's largest Q2 2023 buy was Teva Pharmaceuticals: 4,250,000 shares worth $32M.
- Soleus Capital Management added most to United Therapeutics in Q2 2023, an estimated $23.6M increase.
- Soleus Capital Management's biggest Q2 2023 reduction was Exact Sciences, cutting an estimated $30.2M.
- Soleus Capital Management fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $51.8M.
- Soleus Capital Management's ten largest holdings make up 43% of its $900M portfolio in Q2 2023.
- Soleus Capital Management opened 38 new positions and closed 14 in Q2 2023.
- Soleus Capital Management's portfolio value fell 6.9% quarter-over-quarter to $900M.
Based on Soleus Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.